Is ALNY stock a Buy, Sell, or Hold?

Based on our analysis, ALNY is currently a WAIT with low confidence. 📊 MIXED SIGNALS: ALNY shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of ALNY stock?

Our analysis estimates the fair value range for ALNY to be between $229.92 and $256.59. The current price is $227.02.

What is the analyst price target for ALNY?

The average Wall Street analyst price target for ALNY is $370.55. This implies a potential upside of 63.2% from current levels.

Alnylam Pharmaceuticals (ALNY) Stock: Buy, Sell, or Hold?

ALNY - Alnylam Pharmaceuticals, Inc.

PHARMACEUTICAL PREPARATIONS

$227.02

-5.66 (-2.43%) ▼

5d: +3.24%

30d: -8.71%

90d: -19.28%

WAIT

LOW Confidence

Protect Your ALNY Gains

Analysis Updated: Oct 12, 2026 12:00 AM ET

Earnings: Oct 29, 2026 15d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Oct 5, 2026 at $218.33 · last confirmed Oct 6, 2026

Strength: 6.6/10

Get Alerted When ALNY Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: ALNY shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$582.99

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$361.99

37.3% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.1x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: ALNY is currently trading at $227.02, which is considered oversold relative to its 30-day fair value range of $229.92 to $256.59. From a valuation perspective, the stock is trading at a discount (Forward PE: 18.3) compared to its historical average (24.1). Remarkably, the market is currently pricing in an annual earnings decline of 8.8% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, ALNY is in a strong downtrend. Immediate support is located at $215.46, while resistance sits at $257.27.

Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $370.55 (+63.2%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $229.92 - $256.59

Company Quality Score 46/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 79.5%

Protect Your Profits

Holding ALNY? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
NEUTRAL: Mixed technical signals (57/100)
BULLISH: High volume confirmation
BULLISH: Trading 63.2% below Wall St target ($370.55)
WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $229.92 - $256.59

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $215.46

Resistance Level $257.27

Current Trend Strong Downtrend

Technical data as of Oct 12, 2026

Fundamental Context

Forward P/E (Next Year Est.) 18.28

Wall Street Target $370.55 (+63.2%)

Revenue Growth (YoY) 66.9%

Profit Margin 16.1%

Valuation Discount vs History -8.8% cheaper

PE vs Historical 18.3 vs 24.1 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -8.8% (market-implied from PE analysis)

1-Year Target $207.04 (-9%)

2-Year Target $188.82 (-17%)

3-Year Target $172.21 (-24%)

3-Yr Target (if PE normalizes) (PE: 18→24) $227.09 (0%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 19.9, Growth: 40.6%) $685.94 (+202%)

Base: (SPY PE: 18.3, Growth: 40.6%) $631.21 (+178%)

Bear: (PE: 15.5, Growth: 40.6%) $536.53 (+136%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (39x PE), but valuation improves significantly next year (18x PE) as earnings recover.

Trailing PE: 39.24 | Current EPS (TTM): $5.93

Bull Case $511.90 (+126%)

Analyst growth 100.0%, PE expands to 43.2

Base Case $465.36 (+105%)

Market implied 100.0%, PE stable at 39.2

Bear Case $158.22 (-30%)

Severe decline -20.0%, PE contracts to 33.4

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 18.3 to 24.1

Stabilization Target: $299.38 (+31.9%)

PE Expansion Potential: +31.9%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: October 12, 2026 10:26 PM ET
Data refreshes hourly during market hours. Next update: 11:26 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is ALNY showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for ALNY.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
DNLI Denali Therapeutics Inc	STRONG BUY 20 analysts	$36	64 BUY
SRRK Scholar Rock Holding Corp	STRONG BUY 18 analysts	$70	59 HOLD
MIRM Mirum Pharmaceuticals Inc	STRONG BUY 14 analysts	$146	73 BUY
ARWR Arrowhead Pharmaceutical…	STRONG BUY 14 analysts	$107	67 BUY
RLAY Relay Therapeutics Inc	STRONG BUY 13 analysts	$28	61 BUY

DNLI Denali Therapeuti…

64 BUY

SRRK Scholar Rock Hold…

59 HOLD

MIRM Mirum Pharmaceuti…

73 BUY

ARWR Arrowhead Pharmac…

67 BUY

RLAY Relay Therapeutic…

61 BUY

Advanced ALNY Option Strategies

Professional options setups generated by AI based on today's ALNY price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ALNY

ALNY Technical Chart ALNY Price Prediction ALNY Earnings Date Why is ALNY Moving Today? ALNY Investment Advisor ALNY Fair Price Analyzer ALNY Options Advisor ALNY Options Chain ALNY Options Analysis ALNY Competitors

Compare ALNY with Peers

ALNY vs BMRN
Which one to buy?

ALNY vs IONS
Which one to buy?

ALNY vs INCY
Which one to buy?

ALNY vs SRPT
Which one to buy?

ALNY vs NBIX
Which one to buy?

HALO vs ALNY
Winner: Tie

Create New Comparison View All Competitors

Tradestie